302P Clinical implication of tissue re-biopsy in metastatic breast cancer (MBC) patients: A single centre retrospective analysis

Carlino, Francesca; Diana, Anna; Terminiello, M.; Ventriglia, Anna; Piccolo, Antonio; Bruno, Vincenzo; LoBianco, L.; Caterino, Marianna; Ciardiello, Fortunato; Daniele, Bruno; Orditura, Michele

doi:10.1016/j.annonc.2021.08.585

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Receptor conversion is a well-documented event in progressive MBC, which results in HR and HER2 status discordance between the primary tumor and metastatic site ( 21 ). An increasing number of guidelines recommend a re-biopsy of metastatic breast cancer to determine the receptor status and molecular subtype ( 22 ).…”

Section: Methodsmentioning

confidence: 99%

Preferences for the sequencing of first-line systemic treatments in metastatic hormone receptor-positive, HER2-negative breast cancer

Al Mahmasani,

Amhaz,

Abou Zeidane

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

IntroductionMetastatic breast cancer (MBC) is a diverse disease. Therapeutic options include hormonal therapy, chemotherapy, and targeted therapies. The optimal treatment sequence for patients with hormone receptor-positive (HR-positive), HER2-negative metastatic breast cancer remains unknown.MethodsThis was a retrospective and prospective study. The data was collected from the medical records of patients in a tertiary healthcare center in Lebanon between the years 2016 and 2019, and patients were followed up for a 3-year duration. The main aim was to identify oncologists’ preferences in the choice and sequence of treatment for newly diagnosed and/or recurrent cases of HR-positive, HER2-negative MBC.ResultsA total of 51 patients were included. 24 patients received chemotherapy, while 27 received endocrine therapy as first-line treatment after a diagnosis of MBC, with a median overall survival (OS) of 13 months and a median progression-free survival (PFS) of 12 months after first-line treatment with chemotherapy, compared to 27 months and 18 months with endocrine therapy. A higher percentage of patients have received chemotherapy in the first-line setting compared to the data reported in the literature, with the choice being multifactorial.ConclusionFactors to consider in MBC management include the choice of first-line treatment, the optimal sequence of treatment, and the combination of available treatment options.

show abstract

Section: Methodsmentioning

confidence: 99%

Preferences for the sequencing of first-line systemic treatments in metastatic hormone receptor-positive, HER2-negative breast cancer

Al Mahmasani,

Amhaz,

Abou Zeidane

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…The BOLERO-2, PrE0102, and GINECO studies demonstrated that everolimus plus endocrine therapy significantly prolonged PFS in postmenopausal HR-positive and HER2-negative advanced BC patients who failed endocrine therapy [ 75 – 77 ]. Meanwhile, BOLERO-4 and BOLERO-5 demonstrated that everolimus, in combination with letrozole and exemestane, respectively, prolonged PFS in this group of patients [ 78 , 79 ]. And the MIRACLE study depicted that everolimus plus endocrine therapy was effective in patients with premenopausal HR-positive and HER2-negative advanced BC [ 80 ].…”

Section: Clinical Data Of Studies Targeting Pi3k Pathway In Tnbcmentioning

confidence: 99%

PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer

Zhang,

Jiang,

Zhu

et al. 2024

Breast Cancer

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is a highly heterogeneous tumor lacking estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. It has higher aggressiveness and metastasis than other subtypes, with limited effective therapeutic strategies, leading to a poor prognosis. The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) signaling pathway is prevalently over-activated in human cancers and contributes to breast cancer (BC) growth, survival, proliferation, and angiogenesis, which could be an interesting therapeutic target. This review summarizes the PI3K/AKT/mTOR signaling pathway activation mechanism in TNBC and discusses the relationship between its activation and various TNBC subtypes. We also report the latest clinical studies on kinase inhibitors related to this pathway for treating TNBC. Our review discusses the issues that need to be addressed in the clinical application of these inhibitors.

show abstract

302P Clinical implication of tissue re-biopsy in metastatic breast cancer (MBC) patients: A single centre retrospective analysis

Cited by 2 publications

References 0 publications

Preferences for the sequencing of first-line systemic treatments in metastatic hormone receptor-positive, HER2-negative breast cancer

Preferences for the sequencing of first-line systemic treatments in metastatic hormone receptor-positive, HER2-negative breast cancer

PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer

Contact Info

Product

Resources

About